High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six to seven hours of structured sessions per day (8 sessions total). In between sessions, roundtable discussions will be held and there are ample opportunities for independent meetings and networking. The 2025 meeting, with anticipated attendance of 100 participants, promises to open avenues and opportunities of collaboration on a variety of issues important to the nuclear medicine and molecular imaging community while allowing interaction and networking.

Over the course of four days, the High Country Nuclear Medicine Conference will offer 27 hours of content. No CE Credit will be offered at the 2025 Conference. The 2025 Conference will only be held in-person.

2025 Program

*All times are Mountain Time. Schedule Subject to Change.

Saturday, March 1, 2025

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM Instrumentation, AI and Data Analysis in Nuclear Medicine
Session Chair: Hans Vija, PhD
Co-Chair: Nicolas A. Karakatsanis, PhD, DABSNM, SM’IEEE 

Title:

     Ultra-performance total-body PET multi-parametric imaging to monitor human physiology and diseases
     Speaker: Nicolas A. Karakatsanis, PhD

     Multi-modality Synergistic Imaging in Nuclear Medicine
     Speaker: Andreas Kjaer, PhD, MD

     Quantitative PET and SPECT Image Reconstruction powered by Artificial Intelligence
     Speaker: Chi Liu, PhD

     The advent of Digital Twins and Personalized Radiation Therapy with Dosimetry
      Speaker: Arman Rahmim, PhD

     Data Utilization for Nuclear Medicine Theranostics and Necessity for Standardization
     Speaker: Julia Brosch-Lenz, PhD

     Round-Table Discussion with Q&A
     Speakers: All session moderators and speakers

1:00 PM – 3:00 PM  Roundtable: Open Discussion on Prostate & Neuroendocrine, lessons learned and to be learned

     Lead: Michael M. Graham, PhD, MD

4:00 PM – 7:30 PM Cardiology Session
Session Chair: Piotr Slmoka, PhD
Co-Chair: Panithaya Chareonthaitawee, MD

Title:

     Carving New Trails in Cardiac PET: The Evolving Landscape of SPECT and PET MPI
     Speaker: Mouaz al-Mallah, MD, MSc

     Slopes Ahead: Are We Ready for Flurpiridaz and Other New PET Perfusion Tracers?
     Speaker: Jamieson Burque, MD

     Fresh Powder in PET MBF: What’s New on the Horizon?
     Speaker: Panithaya Chareothaitawee, MD

     Shredding the Data: AI Insights from PET/CT Attenuation Maps
     Speaker: Piotr Slomka, PhD

     Hitting the Slopes with New PET Tracers for Amyloid Imaging
     Speaker: Sarah Cuddy, MD

Sunday, March 2, 2025

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM Latest Developments in Pediatric Nuclear Medicine – Imaging & Therapy
Session Chair: Helen Nadel, MD FRCPC (Diag Rad) (Nuc Med), ABR (Ped Rad), ABNM, FACNM, FSNMMI
Co-Chair: Alan Packard, PhD

Title:

     Monitoring Pediatric Patients with Cancer Predisposition Syndromes with PET
     Speaker: Helen Nadel, MD FRCPC (Diag Rad) (Nuc Med), ABR (Ped Rad), ABNM, FACNM, FSNMMI

     Why are PET and SPECT images essential for pediatric epilepsy evaluation?
     Speaker: Maria Rosana Ponisio, MD

     New Therapeutic Options for Recurrent Neuroblastoma, from small molecules to antibodies
     Speaker: Alan Packard, PhD

     Early experience with EFOV PET CT in a pediatric oncology population
     Speaker: Barry Shulkin, MD

1:00 PM – 3:00 PM  Roundtable: SIRT
     Lead: Michael Wissmeyer, MD

4:30 PM – 6:00 PM Hal O’Brien Rising Star Session
Session Chair: Piotr Slomka, PhD
Co-Chair: Peter Conti, PhD, MD

     Session TBD
     Speaker: Brittany Weber, PhD

     Session TBD
     Speaker: Carlos Uribe, PhD

6:00 PM – 7:00 PM Past President Discussion of the future of Nuclear Medicine
Moderator: Alan Packard, PhD

Top Reasons to attend:
    – Where the Society was vs Where it is going?
    – Where is the future in nuclear medicine?
    – How to become the next SNMMI President.
    – Where are we getting the next generation of Nuclear Medicine Practitioners?

Past Presidents:
     Helen Nadel, MD FRCPC (Diag Rad) (Nuc Med), ABR (Ped Rad), ABNM, FACNM, FSNMMI
     Peter Conti, PhD, MD
     Michael Graham, PhD, MD
     Alan Packard, PhD
     Richard Wahl, MD, FACR
     Cathy Cutler, PhD, FSNMMI
     Satoshi Minoshima, PhD, MD

7:00 PM – 9:00 PM Sunday Night Dinner & Hal O’Brien Rising Star Award Ceremony. Open to all in-person attendees with meeting registration. Additional tickets available for guests.

Monday, March 3, 2025

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM Regulatory Session
Session Chair: Ira Goldman, MA
Co-Chair: Cathy Cutler, PhD, FSNMMI

Title:

     SNMMI Government Affairs Activities
     Speaker: Cathy Cutler, PhD, FSNMMI

     Radiopharmaceutical Product Quality
     Speaker: TBD

     Prospects for use of AI in nuclear medicine
     Speaker: TBD

     NRC Rulemaking and Guidance related to Nuclear Medicine
     Speaker: TBD

1:00 PM – 3:00 PM  Roundtable: Cognitive impairment: Nuclear Medicine in the Patient journey
     Lead: Maria Rosana Ponisio, MD

4:00 PM- 7:30 PM Theranostic including Alpha trials #1 (cutting edge focus / radiobiology)
Session Chair: Andreas Kjaer, PhD, MD
Co-Chair: Richard Wahl, PhD, MD

Title:

     Radiobiology of alpha and beta emitters: do we understand it?
     Speaker: Edward O’Neill, PhD

     Which alpha emitter to pick: pros and cons beyond availability
     Speaker: Andreas Kjaer, MD, PhD

     Dosimetry in drug development and patient management
     Speaker: Stephen A Graves, PhD

     Radiolabeled monoclonal antibodies as theranostics revisited
     Speaker: Richard Wahl, PhD, MD

     Pretargeting for Radiotheranostics
     Speaker: Andreas Kjaer, PhD, MD

Tuesday, March 4, 2025

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM Theranostics #2 (clinical trial focus)
Session Chair: Richard Wahl, PhD, MD
Co-Chair: Andreas Kjaer, PhD, MD

Title:

     Will We Have Sufficient Alpha and Beta Therapeutic Radionuclides to Meet Demand?
     Speaker: Roy Brown, BS, MBA

     Targeted Alpha Therapy (TAT) in SSTR expressing neuroendocrine tumors with Pb-212-DOTAMTATE (AlphaMedix ™), in PRRT naïve and progressed settings- The latest Phase II results
     Speaker: Ebrahim Delpassand, MD

     Initial Clinical Experience with Pb212 VMT alpha NET in patients with Neuroendocrine Tumors: Feasibility, Toxicity, and early Clinical Results
     Speaker: Vikas Prasad, PhD

     The first-in-human, phase I study of an actinium-225-labeled antibody targeting human kallikrein 2 in patients with metastatic castration-resistant prostate cancer
     Speaker: Won Kim

     Panel Discussion

1:00 PM – 3:00 PM  Roundtable: Dosimetry & Post Treatment Spect
     Lead: Michael Graham, PhD, MD and Richard Wahl, PhD, MD

4:00 PM- 7:30 PM Neurology Session
Session Chair: Andrew Stephens, PhD, MD
Co-Chair: Neil Vasdev, Ph.D., ACSF, FRSC (UK), FSNMMI

Title:

     Revised Criteria for Diagnosis and Staging and their clinical implications
     Speaker: Mary Ellen Koran, PhD, MD

     Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
     Speaker: Renaud La Joie, PhD

     Recent Progress for Imaging Traumatic Brain Injuries
     Speaker: Carmela Tartaglia, MD, FRCPC

     AD: one year after disease modification therapy and its reimbursement
     Speaker: Ana Franceschi, PhD, MD

     Dominantly Inherited Alzheimer’s Disease
     Speaker: Tammy Benzinger, PhD, MD

     PET imaging in non-AD neurodegeneration
     Speaker: Maura Malpetti, PhD